JAGX_OUT_1 [2025-04-25 11:25:17 -0400] 6049 Bytes | 1586 tokens | Cum: 1586 tkns (19.82% of 8k)
==========================================================================

Booyah, my friends! It's already 11:25 AM on Fri Apr 25, 2025, and I've got my eyes locked on Jaguar Health (JAGX), pushing up to $9.78 from $8.06. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: Jaguar Health (JAGX)
IPO: 2015-05-13 (9 Years Ago)
Market Cap: $3,713,768
Shares Outstanding: 670,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Here’s a list of headlines for Jaguar Health:

Apr-17-25 09:00AM - Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress
Apr-16-25 09:50AM - Jaguar Health to present results from OnTarget study in breast cancer patients
Apr-15-25 09:30AM - Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting
Apr-08-25 08:30AM - Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product
Apr-04-25 04:15PM - Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr-01-25 04:15PM - Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules
Mar-31-25 09:57AM - Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call Transcript
Mar-31-25 09:57AM 08:00AM - Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
Mar-28-25 09:00AM - 83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey
Mar-27-25 08:30AM - Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
Mar-26-25 11:00AM - Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts
Mar-26-25 11:00AM 09:25AM - Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules
Mar-26-25 11:00AM 07:00AM - Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now
Mar-25-25 07:00AM - Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now
Mar-18-25 08:30AM - Jaguar Health, Inc. Announces Reverse Stock Split
Mar-13-25 04:15PM - Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
Feb-27-25 08:30AM - Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value
Feb-19-25 09:00AM - Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Feb-18-25 09:00AM - Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
Feb-18-25 09:00AM 07:00AM - Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now
Feb-13-25 09:05AM - Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Feb-06-25 10:00AM - Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-07-23T16:39:12Z - Why Jaguar Health Stock Is Crashing - Benzinga
B2 - 2024-07-16T21:47:51Z - Jaguar Health issues shares to reduce royalty debt - Investing.com
B3 - 2024-05-06T10:43:00Z - Picking Energy Penny Stocks, 3 Tips to Use
B4 - 2024-05-04T11:51:00Z - Choosing the Right Trading Style for Penny Stocks
B5 - 2024-05-03T10:53:00Z - How Penny Stocks Diversify Your Trading Portfolio
B6 - 2024-05-01T10:14:00Z - Investing in Tech Penny Stocks Right Now, 3 Tips

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Jaguar Health (JAGX).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

JAGX_OUT_3 [2025-04-25 11:25:17 -0400] 690 Bytes | 190 tokens | Cum: 1778 tkns (22.23% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Why Jaguar Health Stock Is Crashing - Benzinga**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/07/39912736/why-jaguar-health-stock-is-crashingJaguar Health shares are falling after the company announced its phase 3 OnTarget trial results for crofelemer did not meet its primary endpoint. The stock has a float of only 4.889 million shares after a 1-for-60 reverse split.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JAGX_OUT_5 [2025-04-25 11:25:18 -0400] 985 Bytes | 290 tokens | Cum: 2070 tkns (25.87% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-24T17:05:54Z - 12 Health Care Stocks Moving In Thursday's Intraday Session - CERo Therapeutics Hldgs (NASDAQ:CERO),...
A2 - 2025-04-17T13:02:00Z - Jaguar Health, Inc.: Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar H...
A3 - 2025-04-17T13:02:53Z - Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to...
A4 - 2025-04-16T13:50:34Z - Jaguar Health to present results from OnTarget study in breast cancer patients...
A5 - 2025-04-15T20:43:41Z - Jaguar Health files to sell 1.29M shares of common stock for holders...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

JAGX_OUT_7 [2025-04-25 11:25:19 -0400] 1181 Bytes | 348 tokens | Cum: 2420 tkns (30.25% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Thursday's Intraday Session - CERo Therapeutics Hldgs (NASDAQ:CERO), BioSig Technologies (NASDAQ:BSGM)**Date: 2025-04-24Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44989024/12-health-care-stocks-moving-in-thursdays-intraday-sessionGainers CERo Therapeutics Hldgs CERO stock moved upwards by 37.6% to $1.1 during Thursday's regular session. The company's market cap stands at $5.9 million. TransCode Therapeutics RNAZ shares increased by 26.43% to $0.4. The market value of their outstanding shares is at $9.2 million. Zhengye Biotechnology ZYBT shares increased by 24.8% to $9.76. The market value of their outstanding shares is at $462.5 million. Community Health Sys CYH shares increased by 24.69% to $3.03. The market value of their outstanding shares is at $420.9 million. As pe

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JAGX_OUT_9 [2025-04-25 11:25:20 -0400] 1181 Bytes | 344 tokens | Cum: 2766 tkns (34.58% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): r the press release, Q1 earnings came out yesterday. BioSig Technologies BSGM shares increased by 23.43% to $0.79. The market value of their outstanding shares is at $19.1 million. Jaguar Health JAGX shares moved upwards by 19.94% to $8.0. The market value of their outstanding shares is at $5.3 million. Losers NuCana NCNA shares decreased by 26.3% to $0.66 during Thursday's regular session. The company's market cap stands at $3.9 million. Intensity Therapeutics INTS shares decreased by 23.85% to $0.99. The company's market cap stands at $15.0 million. Ensysce Biosciences ENSC shares declined by 16.08% to $3.08. The company's market cap stands at $5.0 million. Metsera MTSR stock fell 15.17% to $20.0. The company's market cap stands at $2.1 billion. Catheter Precision VTAK stock declined by 12.5% to $0.28. The market value of their outstanding shares is at $2.2 million. Plus Therapeutics P

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JAGX_OUT_11 [2025-04-25 11:25:20 -0400] 1181 Bytes | 386 tokens | Cum: 3154 tkns (39.42% of 8k)
==========================================================================

Showing A1 (chunk 3 of 4): STV shares decreased by 11.41% to $0.87. The market value of their outstanding shares is at $5.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGMBioSig Technologies Inc$0.780021.9%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum15.59Growth84.23Quality-Value2.67Price TrendShortMediumLongOverviewCEROCERo Therapeutics Holdings Inc$1.1240.1%CYHCommunity Health Systems Inc$3.0224.2%ENSCEnsysce Biosciences Inc$3.08-16.2%INTSIntensity Therapeutics Inc$0.9900-23.9%JAGXJaguar Health Inc$8.1021.4%MTSRMetsera Inc$20.02-15.1%NCNANuCana PLC$0.6587-26.0%PSTVPlus Therapeutics Inc$0.8828-10.2%RNAZTransCode Therapeutics Inc$0.380321.1%VTAKCatheter Precision Inc$0.3038-5.06%ZYBTZhengye Biotechnology

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JAGX_OUT_13 [2025-04-25 11:25:21 -0400] 357 Bytes | 107 tokens | Cum: 3263 tkns (40.79% of 8k)
==========================================================================

Showing A1 (chunk 4 of 4): Holding Ltd$9.8425.8%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JAGX_OUT_15 [2025-04-25 11:25:22 -0400] 829 Bytes | 231 tokens | Cum: 3496 tkns (43.70% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-18 8-K Item 7.01 Regulation FD Disclosure. Jaguar Health, Inc. (the Company) is scheduled to make a presentation at the 11 th Annual Elite Ped-GI Congress 2025 on April 24 to April 26, 2025 in Abu Dhabi, UAR. During the conference and in separate sessions with investors, the Companys Ch...

S10 - 2025-03-31 8-K Item 2.02 Results of Oper and Fin Cond.

On March 31, 2025, Jaguar Health, Inc. (the Company) issued a press release announcing 2024 results. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in Item 2.02 and the press r...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

JAGX_OUT_17 [2025-04-25 11:25:22 -0400] 1097 Bytes | 276 tokens | Cum: 3774 tkns (47.17% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 7.01 Regulation FD Disclosure. Jaguar Health, Inc. (the Company) is scheduled to make a presentation at the 11 th Annual Elite Ped-GI Congress 2025 on April 24 to April 26, 2025 in Abu Dhabi, UAR. During the conference and in separate sessions with investors, the Companys Chief Executive Officer will refer to an updated investor presentation, a copy of which is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JAGX_OUT_19 [2025-04-25 11:25:28 -0400] 7643 Bytes | 2169 tokens | Cum: 5945 tkns (74.31% of 8k)
==========================================================================

This is our set of metrics for Jaguar Health.
Please analyze the numbers.

+--------------------+-----------------------+-----------------------+-------------------------+
| Volume: 103,566 | Perf Month: 84.50% | Option/Short: No / No | Sales Y/Y TTM: 19.75% |
+--------------------+-----------------------+-----------------------+-------------------------+
| Avg Volume: 38.44K | Perf Quarter: -55.93% | Short Float: 9.12% | ROE: -522.60% |
+--------------------+-----------------------+-----------------------+-------------------------+
| Rel Volume: 9.25 | Index: - | Short Ratio: 1.33 | ROI: -113.35% |
+--------------------+-----------------------+-----------------------+-------------------------+
| RSI (14): 65.14 | Market Cap: 6.38M | Short Interest: 0.05M | Sales Surprise: -21.36% |
+--------------------+-----------------------+-----------------------+-------------------------+
| ATR (14): 1.05 | Shs Outstand: 0.67M | Beta: 1.00 | EPS Surprise: 55.70% |
+--------------------+-----------------------+-----------------------+-------------------------+
| SMA20: 70.97% | Shs Float: 0.56M | Sales Q/Q: 52.57% | P/E: - |
+--------------------+-----------------------+-----------------------+-------------------------+
| SMA50: -9.40% | Inst Own: 1.67% | Sales past 5Y: 37.18% | Earnings: Nov 13 BMO |
+--------------------+-----------------------+-----------------------+-------------------------+
| SMA200: -63.93% | Insider Own: 16.58% | Employees: 49 | |
+--------------------+-----------------------+-----------------------+-------------------------+
| Perf Week: 71.78% | Insider Trans: 0.00% | Debt/Eq: 3.74 | |
+--------------------+-----------------------+-----------------------+-------------------------+

The next section covers any insider trading by Jaguar Health officers or majority shareholders (if available).

Inside Trans: Jaguar Health, Inc. (JAGX) by Lizak Carol R. (Chief Financial Officer) on 2025-03-31
- Convertible Promissory Note: 5400 shares at $30000 (D)
- Warrant to Purchase Common Stock: 5400 shares at $N/A (D)

Inside Trans: Jaguar Health, Inc. (JAGX) by Wolin Jonathan S. (See Remarks) on 2025-03-31
- Convertible Promissory Note: 9000 shares at $50000 (D)
- Warrant to Purchase Common Stock: 9000 shares at $N/A (D)

Inside Trans: Jaguar Health, Inc. (JAGX) by BOCHNOWSKI JAMES J (Unknown Title) on 2025-03-31
- Convertible Promissory Note: 27002 shares at $150000 (I)
- Warrant to Purchase Common Stock: 27002 shares at $N/A (I)

Inside Trans: Jaguar Health, Inc. (JAGX) by Chaturvedi Pravin R (Chief Scientific Officer) on 2025-03-31
- Convertible Promissory Note: 3600 shares at $20000 (D)
- Warrant to Purchase Common Stock: 3600 shares at $N/A (D)

Inside Trans: Jaguar Health, Inc. (JAGX) by CONTE LISA A (CEO and President) on 2025-03-31
- Convertible Promissory Note: 9000 shares at $50000 (D)
- Warrant to Purchase Common Stock: 9000 shares at $N/A (D)

Inside Trans: Jaguar Health, Inc. (JAGX) by Siegel Jonathan B. (Unknown Title) on 2025-03-31
- Convertible Promissory Note: 9000 shares at $50000 (I)
- Warrant to Purchase Common Stock: 9000 shares at $N/A (I)

Inside Trans: Jaguar Health, Inc. (JAGX) by King Steven R. (See Remarks) on 2025-03-31
- Convertible Promissory Note: 3600 shares at $20000 (D)
- Warrant to Purchase Common Stock: 3600 shares at $N/A (D)

Inside Trans: Jaguar Health, Inc. (JAGX) by MICEK JOHN (Unknown Title) on 2025-03-31
- Convertible Promissory Note: 9000 shares at $50000 (D)
- Warrant to Purchase Common Stock: 9000 shares at $N/A (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 10480000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -38326000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 9.64
Average Volume: 68574.18
30-Day High: 9.64
30-Day Low: 4.37

[Detailed Financials: Q3 2024]
- Total Assets: $58,466,000.00
- Total Liabilities: $42,883,000.00
- Total Equity: $13,098,000.00
- Current Assets: $36,643,000.00
- Current Liabilities: $19,874,000.00

[Income Statement: Q3 2024]
- Revenue: $3,108,000.00
- Net Income: $-10,021,000.00
- Gross Profit: $2,567,000.00
- Operating Income: $-7,262,000.00
- Earnings Per Share (EPS): -1.05

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-2,811,000.00

[Detailed Financials: Q2 2024]
- Total Assets: $61,459,000.00
- Total Liabilities: $42,396,000.00
- Total Equity: $16,578,000.00
- Current Assets: $40,111,000.00
- Current Liabilities: $19,133,000.00

[Income Statement: Q2 2024]
- Revenue: $2,721,000.00
- Net Income: $-9,628,000.00
- Gross Profit: $2,294,000.00
- Operating Income: $-7,197,000.00
- Earnings Per Share (EPS): -4.04

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $9,609,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Jaguar Health (JAGX).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Jaguar Health.

2) MARKET_SCORE[]
This conversation was initiated because JAGX is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for JAGX.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, JAGX could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect JAGX to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Jaguar Health.

11) ETHICAL_RATING[]
Rate Jaguar Health’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Jaguar Health.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

JAGX_IN_21 [2025-04-25 11:25:28 -0400] 126 Bytes | 29 tokens | Cum: 6190 tkns (77.38% of 8k)
==========================================================================

====================================
[2025-04-25 11:25:28] # Analysis Completed
Elapsed Time: 12.37 seconds